169 related articles for article (PubMed ID: 31714353)
1. Immune effects of Lactobacillus casei Shirota in treated HIV-infected patients with poor CD4+ T-cell recovery.
Tenore SB; Avelino-Silva VI; Costa PR; Franco LM; Sabino EC; Kalil J; Cerqueira NB; Nakagawa Z; Kallas EG
AIDS; 2020 Mar; 34(3):381-389. PubMed ID: 31714353
[TBL] [Abstract][Full Text] [Related]
2. Probiotic effects on immunity and microbiome in HIV-1 discordant patients.
Blázquez-Bondia C; Parera M; Català-Moll F; Casadellà M; Elizalde-Torrent A; Aguiló M; Espadaler-Mazo J; Santos JR; Paredes R; Noguera-Julian M
Front Immunol; 2022; 13():1066036. PubMed ID: 36569851
[TBL] [Abstract][Full Text] [Related]
3. Variation in blood microbial lipopolysaccharide (LPS) contributes to immune reconstitution in response to suppressive antiretroviral therapy in HIV.
Luo Z; Health SL; Li M; Yang H; Wu Y; Collins M; Deeks SG; Martin JN; Scott A; Jiang W
EBioMedicine; 2022 Jun; 80():104037. PubMed ID: 35500539
[TBL] [Abstract][Full Text] [Related]
4. Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials.
Kim CJ; Walmsley SL; Raboud JM; Kovacs C; Coburn B; Rousseau R; Reinhard R; Rosenes R; Kaul R
HIV Clin Trials; 2016 Jul; 17(4):147-57. PubMed ID: 27267710
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial.
Nakanjako D; Ssinabulya I; Nabatanzi R; Bayigga L; Kiragga A; Joloba M; Kaleebu P; Kambugu AD; Kamya MR; Sekaly R; Elliott A; Mayanja-Kizza H
Trop Med Int Health; 2015 Mar; 20(3):380-90. PubMed ID: 25441397
[TBL] [Abstract][Full Text] [Related]
6. Effects of Short-Term Probiotic Ingestion on Immune Profiles and Microbial Translocation among HIV-1-Infected Vietnamese Children.
Ishizaki A; Bi X; Nguyen LV; Matsuda K; Pham HV; Phan CTT; Khu DTK; Ichimura H
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29048352
[TBL] [Abstract][Full Text] [Related]
7. Association between CD4
Lu D; Zhang JB; Wang YX; Geng ST; Zhang Z; Xu Y; Li SY; Wang KH; Kuang YQ
BMC Infect Dis; 2021 Aug; 21(1):742. PubMed ID: 34344350
[TBL] [Abstract][Full Text] [Related]
8. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.
Paton NI; Goodall RL; Dunn DT; Franzen S; Collaco-Moraes Y; Gazzard BG; Williams IG; Fisher MJ; Winston A; Fox J; Orkin C; Herieka EA; Ainsworth JG; Post FA; Wansbrough-Jones M; Kelleher P;
JAMA; 2012 Jul; 308(4):353-61. PubMed ID: 22820788
[TBL] [Abstract][Full Text] [Related]
9. Determinants of suboptimal CD4
Handoko R; Colby DJ; Kroon E; Sacdalan C; de Souza M; Pinyakorn S; Prueksakaew P; Munkong C; Ubolyam S; Akapirat S; Chiarella J; Krebs S; Sereti I; Valcour V; Paul R; Michael NL; Phanuphak N; Ananworanich J; Spudich S;
J Int AIDS Soc; 2020 Sep; 23(9):e25585. PubMed ID: 32949118
[TBL] [Abstract][Full Text] [Related]
10. Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study).
Serrano-Villar S; de Lagarde M; Vázquez-Castellanos J; Vallejo A; Bernadino JI; Madrid N; Matarranz M; Díaz-Santiago A; Gutiérrez C; Cabello A; Villar-García J; Blanco JR; Bisbal O; Sainz T; Moya A; Moreno S; Gosalbes MJ; Estrada V
Clin Infect Dis; 2019 Jan; 68(1):120-130. PubMed ID: 29788075
[TBL] [Abstract][Full Text] [Related]
11. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
12. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy.
Routy JP; Angel JB; Patel M; Kanagaratham C; Radzioch D; Kema I; Gilmore N; Ancuta P; Singer J; Jenabian MA
HIV Med; 2015 Jan; 16(1):48-56. PubMed ID: 24889179
[TBL] [Abstract][Full Text] [Related]
13. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.
Massanella M; Negredo E; Puig J; Puertas MC; Buzón MJ; Pérez-Álvarez N; Carrillo J; Clotet B; Martínez-Picado J; Blanco J
AIDS; 2012 Nov; 26(18):2285-93. PubMed ID: 23018435
[TBL] [Abstract][Full Text] [Related]
14. Randomized, Blinded, Placebo-Controlled Trial of De Simone Formulation Probiotic During HIV-Associated Suboptimal CD4+ T Cell Recovery.
Rousseau RK; Walmsley SL; Lee T; Rosenes R; Reinhard RJ; Malazogu F; Benko E; Huibner S; Kovacs CM; Singer J; Kim CJ; Kaul R
J Acquir Immune Defic Syndr; 2022 Feb; 89(2):199-207. PubMed ID: 34693932
[TBL] [Abstract][Full Text] [Related]
15. Preservation of Gastrointestinal Mucosal Barrier Function and Microbiome in Patients With Controlled HIV Infection.
Mak G; Zaunders JJ; Bailey M; Seddiki N; Rogers G; Leong L; Phan TG; Kelleher AD; Koelsch KK; Boyd MA; Danta M
Front Immunol; 2021; 12():688886. PubMed ID: 34135912
[TBL] [Abstract][Full Text] [Related]
16. Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy.
Tincati C; Merlini E; Braidotti P; Ancona G; Savi F; Tosi D; Borghi E; Callegari ML; Mangiavillano B; Barassi A; Bulfamante G; d'Arminio Monforte A; Romagnoli S; Chomont N; Marchetti G
AIDS; 2016 Apr; 30(7):991-1003. PubMed ID: 27028142
[TBL] [Abstract][Full Text] [Related]
17. Effect of selenium supplementation on CD4+ T-cell recovery, viral suppression and morbidity of HIV-infected patients in Rwanda: a randomized controlled trial.
Kamwesiga J; Mutabazi V; Kayumba J; Tayari JC; Uwimbabazi JC; Batanage G; Uwera G; Baziruwiha M; Ntizimira C; Murebwayire A; Haguma JP; Nyiransabimana J; Nzabandora JB; Nzamwita P; Mukazayire E;
AIDS; 2015 Jun; 29(9):1045-52. PubMed ID: 25870994
[TBL] [Abstract][Full Text] [Related]
18. A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection.
Dubé MP; Chan ES; Lake JE; Williams B; Kinslow J; Landay A; Coombs RW; Floris-Moore M; Ribaudo HJ; Yarasheski KE
Clin Infect Dis; 2019 Sep; 69(7):1165-1172. PubMed ID: 30535188
[TBL] [Abstract][Full Text] [Related]
19. HIV Reservoir Decay and CD4 Recovery Associated With High CD8 Counts in Immune Restored Patients on Long-Term ART.
Zhang LX; Jiao YM; Zhang C; Song JW; Fan X; Xu RN; Huang HH; Zhang JY; Wang LF; Zhou CB; Jin L; Shi M; Wang FS
Front Immunol; 2020; 11():1541. PubMed ID: 32793212
[No Abstract] [Full Text] [Related]
20. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.
Byakwaga H; Kelly M; Purcell DF; French MA; Amin J; Lewin SR; Haskelberg H; Kelleher AD; Garsia R; Boyd MA; Cooper DA; Emery S;
J Infect Dis; 2011 Nov; 204(10):1532-40. PubMed ID: 21930607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
